Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial
Sign Up to like & getrecommendations! Published in 2024 at "Future Oncology"
DOI: 10.1080/14796694.2024.2351353
Abstract: Aim: To perform a cost–effectiveness analysis comparing axicabtagene ciloleucel (axi-cel) with standard of care (SoC; salvage chemoimmunotherapy, followed by high-dose therapy with autologous stem cell rescue for responders) for second-line (2L) treatment of adults with… read more here.
Keywords: standard care; zuma trial; axicabtagene ciloleucel; cost ... See more keywords